Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

BUY
$12.17 - $24.61 $173,033 - $349,904
14,218 Added 42.01%
48,060 $1.01 Million
Q4 2023

Jan 26, 2024

SELL
$12.89 - $20.82 $34,545 - $55,797
-2,680 Reduced 7.34%
33,842 $607,000
Q3 2023

Nov 03, 2023

SELL
$16.46 - $19.99 $3,440 - $4,177
-209 Reduced 0.57%
36,522 $601,000
Q2 2023

Aug 04, 2023

BUY
$17.23 - $21.71 $124,934 - $157,419
7,251 Added 24.6%
36,731 $734,000
Q1 2023

May 15, 2023

BUY
$18.08 - $24.55 $11,318 - $15,368
626 Added 2.17%
29,480 $557,000
Q4 2022

Feb 15, 2023

SELL
$20.4 - $24.73 $11,505 - $13,947
-564 Reduced 1.92%
28,854 $654,000
Q3 2022

Nov 16, 2022

BUY
$22.29 - $35.04 $37,692 - $59,252
1,691 Added 6.1%
29,418 $778,000
Q2 2022

Aug 01, 2022

SELL
$19.35 - $35.04 $40,112 - $72,637
-2,073 Reduced 6.96%
27,727 $1.08 Million
Q1 2022

May 03, 2022

BUY
$24.62 - $34.31 $6,819 - $9,503
277 Added 0.94%
29,800 $989,000
Q4 2021

Jan 21, 2022

BUY
$30.19 - $40.28 $30,673 - $40,924
1,016 Added 3.56%
29,523 $965,000
Q3 2021

Oct 20, 2021

BUY
$29.09 - $45.68 $22,690 - $35,630
780 Added 2.81%
28,507 $1.2 Million
Q2 2021

Jul 20, 2021

BUY
$32.46 - $40.48 $55,441 - $69,139
1,708 Added 6.56%
27,727 $1.08 Million
Q1 2021

Apr 06, 2021

SELL
$33.61 - $49.95 $25,778 - $38,311
-767 Reduced 2.86%
26,019 $888,000
Q4 2020

Jan 20, 2021

BUY
$26.52 - $49.35 $981 - $1,825
37 Added 0.14%
26,786 $1.22 Million
Q3 2020

Nov 03, 2020

BUY
$27.01 - $40.26 $190,258 - $283,591
7,044 Added 35.75%
26,749 $736,000
Q2 2020

Jul 22, 2020

SELL
$27.75 - $43.44 $15,262 - $23,892
-550 Reduced 2.72%
19,705 $726,000
Q1 2020

Apr 22, 2020

SELL
$21.5 - $54.2 $15,910 - $40,108
-740 Reduced 3.52%
20,255 $656,000
Q4 2019

Apr 22, 2020

BUY
$34.54 - $44.87 $725,167 - $942,045
20,995 New
20,995 $860,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Liberty One Investment Management, LLC Portfolio

Follow Liberty One Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Liberty One Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Liberty One Investment Management, LLC with notifications on news.